KR20240039001A - 향상된 imid 활성으로 btk를 분해하기 위한 이작용성 화합물 - Google Patents

향상된 imid 활성으로 btk를 분해하기 위한 이작용성 화합물 Download PDF

Info

Publication number
KR20240039001A
KR20240039001A KR1020247006052A KR20247006052A KR20240039001A KR 20240039001 A KR20240039001 A KR 20240039001A KR 1020247006052 A KR1020247006052 A KR 1020247006052A KR 20247006052 A KR20247006052 A KR 20247006052A KR 20240039001 A KR20240039001 A KR 20240039001A
Authority
KR
South Korea
Prior art keywords
alkyl
membered
heterocycloalkyl
compound
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247006052A
Other languages
English (en)
Korean (ko)
Inventor
크리스티아나 귀두치
마크 노비스키
Original Assignee
누릭스 테라퓨틱스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 누릭스 테라퓨틱스 인코포레이티드 filed Critical 누릭스 테라퓨틱스 인코포레이티드
Publication of KR20240039001A publication Critical patent/KR20240039001A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020247006052A 2021-07-23 2022-07-22 향상된 imid 활성으로 btk를 분해하기 위한 이작용성 화합물 Pending KR20240039001A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163225401P 2021-07-23 2021-07-23
US63/225,401 2021-07-23
PCT/US2022/038084 WO2023004163A1 (en) 2021-07-23 2022-07-22 Bifunctional compounds for degrading btk with enhanced imid activity

Publications (1)

Publication Number Publication Date
KR20240039001A true KR20240039001A (ko) 2024-03-26

Family

ID=82898772

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247006052A Pending KR20240039001A (ko) 2021-07-23 2022-07-22 향상된 imid 활성으로 btk를 분해하기 위한 이작용성 화합물

Country Status (10)

Country Link
US (1) US20250017922A1 (https=)
EP (1) EP4373493A1 (https=)
JP (1) JP2024526984A (https=)
KR (1) KR20240039001A (https=)
CN (1) CN118019539A (https=)
AU (1) AU2022313210A1 (https=)
CA (1) CA3226590A1 (https=)
IL (1) IL310269A (https=)
MX (1) MX2024000947A (https=)
WO (1) WO2023004163A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7600123B2 (ja) 2018-10-15 2024-12-16 ニューリックス セラピューティクス，インコーポレイテッド ユビキチンプロテオソーム経路を介してｂｔｋを分解するための二官能性化合物
WO2020167518A1 (en) 2019-02-13 2020-08-20 Nurix Therapeutics, Inc. Bifunctional compounds for degrading btk via ubiquitin proteosome pathway
US11820781B2 (en) 2019-12-04 2023-11-21 Nurix Therapeutics, Inc. Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway
CN115557933B (zh) * 2021-07-01 2024-08-16 杭州和正医药有限公司 布鲁顿酪氨酸激酶及其突变体降解剂、组合物及应用
AU2022379494A1 (en) * 2021-10-26 2024-05-30 Nurix Therapeutics, Inc. Piperidinylpyrazine-carboxamide compounds for treating and preventing cancer and for degrading btk
CN120202200A (zh) * 2023-06-01 2025-06-24 标新生物医药科技(上海)有限公司 基于氧代异吲哚啉基取代的四氢嘧啶二酮的化合物及其应用
CN121335894A (zh) * 2024-02-04 2026-01-13 上海超阳药业有限公司 一种具备降解酪氨酸蛋白激酶btk活性的化合物及其制备方法和用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7600123B2 (ja) 2018-10-15 2024-12-16 ニューリックス セラピューティクス，インコーポレイテッド ユビキチンプロテオソーム経路を介してｂｔｋを分解するための二官能性化合物
US11820781B2 (en) 2019-12-04 2023-11-21 Nurix Therapeutics, Inc. Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway

Also Published As

Publication number Publication date
CA3226590A1 (en) 2023-01-26
CN118019539A (zh) 2024-05-10
IL310269A (en) 2024-03-01
AU2022313210A1 (en) 2024-02-08
EP4373493A1 (en) 2024-05-29
JP2024526984A (ja) 2024-07-19
WO2023004163A1 (en) 2023-01-26
MX2024000947A (es) 2024-04-12
US20250017922A1 (en) 2025-01-16

Similar Documents

Publication Publication Date Title
EP4069237B1 (en) Bifunctional compounds for degrading btk via ubiquitin proteosome pathway
KR20240039001A (ko) 향상된 imid 활성으로 btk를 분해하기 위한 이작용성 화합물
US12582722B2 (en) Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway
US20240336595A1 (en) Bifunctional compounds for degrading btk with diminished imid activity
AU2022270089A1 (en) Compounds for inhibiting or degrading target proteins, compositions, comprising the same, methods of their making, and methods of their use
KR20210077719A (ko) 유비퀴틴 프로테오좀 경로를 통해 btk를 분해시키기 위한 이작용성 화합물
US20250002489A1 (en) Bifunctional compounds for degrading itk via ubiquitin proteosome pathway
US7786107B2 (en) Modulators of muscarinic receptors
BR122023025072A2 (pt) Usos de compostos bifuncionais para degradar btk por meio da via da ubiquitina-proteossoma
HK40081936A (en) Bifunctional compounds for degrading btk via ubiquitin proteosome pathway

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000